Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Depreciation & Amortization (CF) (2017 - 2025)

Aclaris Therapeutics has reported Depreciation & Amortization (CF) over the past 9 years, most recently at $102000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $102000.0 for Q4 2025, down 28.67% from a year ago — trailing twelve months through Dec 2025 was $454000.0 (down 43.74% YoY), and the annual figure for FY2025 was $454000.0, down 43.74%.
  • Depreciation & Amortization (CF) for Q4 2025 was $102000.0 at Aclaris Therapeutics, down from $110000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for ACRS hit a ceiling of $288000.0 in Q1 2021 and a floor of $102000.0 in Q4 2025.
  • Median Depreciation & Amortization (CF) over the past 5 years was $197500.0 (2021), compared with a mean of $192200.0.
  • Peak annual rise in Depreciation & Amortization (CF) hit 143.88% in 2021, while the deepest fall reached 67.68% in 2021.
  • Aclaris Therapeutics' Depreciation & Amortization (CF) stood at $197000.0 in 2021, then dropped by 3.55% to $190000.0 in 2022, then increased by 20.0% to $228000.0 in 2023, then crashed by 37.28% to $143000.0 in 2024, then fell by 28.67% to $102000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $102000.0 (Q4 2025), $110000.0 (Q3 2025), and $114000.0 (Q2 2025) per Business Quant data.